%0 Journal Article %A HYUN-AH KIM %A MIN-KI SEONG %A JI HYUN KIM %A YUN GYOUNG KIM %A HYANG SUK CHOI %A JAE-SUNG KIM %A IN-CHUL PARK %A HYEON-OK JIN %A JIN KYUNG LEE %A WOO CHUL NOH %T Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer %D 2016 %J Anticancer Research %P 1051-1057 %V 36 %N 3 %X Aim: We investigated whether the ovarian reserve determined on the basis of anti-Müllerian hormone (AMH) and inhibin B predicted disease-free survival (DFS) in premenopausal patients with hormone receptor-positive breast cancer treated with neoadjuvant chemotherapy. Patients and Methods: Our analysis included 32 premenopausal women with clinical stage III hormone receptor-positive invasive ductal breast cancer treated by neoadjuvant chemotherapy. Blood samples were obtained after neoadjuvant chemotherapy completion. The median follow-up period was 57.7 months. Results: The median patient age was 41.5 years. The group with functional ovarian reserve was classified by higher AMH and higher inhibin B levels using cut-off values of 1,000 pg/ml and 30 pg/ml, respectively. The group with functional ovarian reserve had significantly worse DFS (p=0.043) than the group with ovarian failure. Conclusion: The functional ovarian reserve defined by higher serum AMH and inhibin B after neoadjuvant chemotherapy predicted poor DFS in premenopausal women with clinical stage III hormone receptor-positive breast cancer. %U https://ar.iiarjournals.org/content/anticanres/36/3/1051.full.pdf